 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 3 | 1 | 4 | | 1997 | 3 | 4 | 7 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 3 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 4 | 4 | | 2004 | 1 | 5 | 6 | | 2005 | 1 | 4 | 5 | | 2006 | 2 | 2 | 4 | | 2007 | 5 | 6 | 11 | | 2008 | 3 | 5 | 8 | | 2009 | 3 | 6 | 9 | | 2010 | 1 | 3 | 4 | | 2011 | 3 | 7 | 10 | | 2012 | 6 | 11 | 17 | | 2013 | 8 | 9 | 17 | | 2014 | 11 | 9 | 20 | | 2015 | 9 | 10 | 19 | | 2016 | 6 | 1 | 7 | | 2017 | 8 | 6 | 14 | | 2018 | 8 | 3 | 11 | | 2019 | 6 | 6 | 12 | | 2020 | 4 | 5 | 9 | | 2021 | 8 | 5 | 13 | | 2022 | 0 | 5 | 5 | | 2023 | 2 | 0 | 2 | | 2024 | 12 | 11 | 23 | | 2025 | 12 | 6 | 18 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Pittman JE, Morgan S, McCreary M, Vu PT, Jorth P, Heltshe S, Hoffman LR, Kelly A, Sagel SD, Singh PK, Solomon GM, Rosenfeld M, Ratjen F. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study. Ann Am Thorac Soc. 2025 Nov; 22(11):1696-1708.
-
Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2025 Oct; 211(10):1926-1934.
-
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 10; 211(10):1901-1914.
-
Lieu CH, Lenz HJ, Benson AB, Meng X, Kim UI, Kim SH, Kim K, Sung MJ. A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors. Cancer Res Commun. 2025 Oct 01; 5(10):1771-1778.
-
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Waltz D, Ahluwalia N, Chu C, Scirica CV, Davies JC. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children =6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Oct; 211(10):1915-1925.
-
Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Stalvey MS, Kelly A. Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):2674-2684.
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
-
Abi-Aad SJ, Trocchia C, Mosha M, Mark JA, Leung DH, Khalaf R. Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Parrett GA, Haft DH, Ruiz M, Garcia-Pichel F, Ebmeier CC, Risser DD. Cyanoexosortase B is essential for motility, biofilm formation, and scytonemin production in a filamentous cyanobacterium. mSphere. 2025 Jun 25; 10(6):e0100624.
-
Leroue MK, Maddux AB, Lehmann T, Niemiec S, Mancuso CA, Khailova L, Mourani PM, Klawitter J, Davidson JA. Alteration in Indole Metabolites After Cardiopulmonary Bypass Surgery in Neonates and Infants. Crit Care Explor. 2025 May 01; 7(5):e1267.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|